Monte Rosa Therapeutics (NASDAQ: GLUE)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.510 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Monte Rosa Therapeutics (NASDAQ: GLUE) through any online brokerage.
Other companies in Monte Rosa Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Kezar Life Sciences (NASDAQ:KZR), Centessa Pharmaceuticals (NASDAQ:CNTA), Inovio Pharmaceuticals (NASDAQ:INO) and Tango Therapeutics (NASDAQ:TNGX).
The latest price target for Monte Rosa Therapeutics (NASDAQ: GLUE) was reported by Piper Sandler on Thursday, May 12, 2022. The analyst firm set a price target for 21.00 expecting GLUE to rise to within 12 months (a possible 107.72% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Monte Rosa Therapeutics (NASDAQ: GLUE) is $10.11 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Monte Rosa Therapeutics.
Monte Rosa Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Monte Rosa Therapeutics.
Monte Rosa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.